Advertisement

Topics

Zynerba's cannabis-based epilepsy gel fails study, shares plunge

04:01 EDT 7 Aug 2017 | Reuters

(Reuters) - Zynerba Pharmaceuticals Inc said on Monday its synthetic cannabis-based gel to treat epilepsy failed a mid-stage study, sending the U.S. drug developer's shares plunging 50 percent.

Original Article: Zynerba's cannabis-based epilepsy gel fails study, shares plunge

NEXT ARTICLE

More From BioPortfolio on "Zynerba's cannabis-based epilepsy gel fails study, shares plunge"

Quick Search
Advertisement
 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...